Found 511 clinical trials
FT516 in Subjects With Advanced Hematologic Malignancies
This is a Phase 1/1b dose-finding study of FT516 as monotherapy in acute myeloid leukemia (AML) and in combination with CD20 directed monoclonal antibodies in B-cell lymphoma. The study includes three stages: dose escalation, safety confirmation, and dose expansion.
- 19 views
- 04 Oct, 2022
- 7 locations
Ruxolitinib and Decitabine for High Risk Hematological Malignancies
The purpose of this study is to determine the efficacy and safety of Ruxolitinib and Decitabine intensified Conditioning Regimen in Patients with High Risk hematological malignancies undergoing
- 0 views
- 25 Jan, 2021
- 1 location
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
This is a phase I, open-label, dose-escalation study to determine the MTD of selumetinib when combined with the standard dose of azacitidine. Treatment will begin within 28 days of screening procedures. Treatment will continue indefinitely, provided that the patient continues to derive benefit. A patient will be taken off study …
- 14 views
- 25 May, 2022
- 1 location
UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies
This is a single arm, open-label, single-center prospective study to determinethe safety and efficacy of CTA30X UCAR-T cells in patients diagnosed with CD19+ refractory/relapsed B Hematologic
- 0 views
- 01 Sep, 2021
- 1 location
A Study of TQB3820 in Patients With Hematological Malignancies
TQB3820 is a novel cereblon-modulating agent. Upon binding to cereblon, a substrate receptor in the cullin4 E3 ligase complex, TQB3820 promotes recruitment, ubiquitination, and subsequent proteasomal degradation of the hematopoietic transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). Modulation of Aiolos and Ikaros expression has the potential to correct multiple aspects …
- 0 views
- 27 Sep, 2021
- 2 locations
Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers
patients with relapsed (the cancer has come back) or refractory (the cancer does not respond or have stopped responding to treatment) acute myeloid leukemia (AML, a type of blood cancer). This study will
- 0 views
- 06 Dec, 2021
- 2 locations
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
If transplantation using mismatched unrelated donors or non-first-degree relatives could be performed with an acceptable toxicity profile, an important unmet need would be served. Towards this goal, the current study extends our platform of nonmyeloablative, partially HLA-mismatched bone marrow transplant (BMT) and Peripheral Blood Stem Cell Transplant (PBSCT) to the …
- 17 views
- 12 Mar, 2022
- 1 location
BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I-II)
This is a Phase I-II, multi-center, open-label, FIH study comprising of 3 study parts (Phase Ia, Phase Ib, and Phase II). The Phase Ia (dose escalation) part of the study is designed to determine the safety, tolerability, and maximum tolerated dose (MTD)/recommended dose for expansion (RP2D) of BR101801 in subjects …
- 19 views
- 08 Dec, 2021
![In-Human CXCR4 Imaging of Blood Cancers Using [68Ga]-Pentixafor-PET](/media/imagery/286076.svg)
In-Human CXCR4 Imaging of Blood Cancers Using [68Ga]-Pentixafor-PET
The purpose of this study is to determine the uptake of the imaging agent [68Ga]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL).
- 0 views
- 13 May, 2022
- 1 location
Phase I Study of Hu8F4 in Patients With Advanced Hematologic Malignancies
This phase I trial studies the side effects and best dose of anti-PR1/HLA-A2 monoclonal antibody Hu8F4 (Hu8F4) in treating patients with malignancies related to the blood (hematologic). Monoclonal antibodies, such as Hu8F4, may interfere with the ability of cancer cells to grow and spread.
- 17 views
- 13 Oct, 2022
- 3 locations